secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001193125-26-071528
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno posts Q4 2025 product revenue of $91.7M; full-year net income $20.9M from VYKAT XR launch
--------------------------------------------------------------------------------

- FY 2025 net income $20.9M ($0.40 basic EPS) vs. net loss of $175.9M in 2024.
- Q4 2025 product revenue $91.7M; full-year revenue $190.4M from VYKAT XR (diazoxide choline).
- 859 active patients on drug as of Dec 31, 2025; 1,250 patient start forms received since approval.
- Cash, cash equivalents and marketable securities $506.1M at year end; $100M share repurchase executed.
- First commercial milestone ($7.0M) achieved in Q4 2025; payment due Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312526071528/0001193125-26-071528-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312526071528/d251192d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-071528

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer